Re: Predicting sustained virological response in chronic hep C therapy

[Guest guest]

Don,

I am very interested in this. I have gotten conflicting information about the

importance of viral load, but this study says it is a factor. My son's viral

load is high. It seems to me that if a drop in viral load is a significant

factor in how well someone is responding to treatment, it must be important

somehow.

I've been told that the clinical trials for telaprevir and boceprevir did not

look at IL22B genotyping. My son has the CC, favorable, genotype. One doc says

his high viral load pretty much wipes out the CC benefits and we need to wait

until the new drugs are available before treating. Another says his chances of

a cure are good enough with the standard 2 drugs because of the CC genotype. Do

you know of any research looking at predicting SVR based on IL22B genotype?

Many thanks!

MM

>

> Predicting sustained virological response in chronic hep C therapy

>  

> Predicting sustained virological response in chronic hep C therapy

>

> A study in the recently published Journal of Viral Hepatitis estimates the

likelihood of sustained virological response in chronic hepatitis C therapy.

>

> The likelihood of a sustained virological response is the most important

factor for physicians and patients in the decision to initiate and continue

therapy for chronic hepatitis C infection.

>

> Dr Stefan Mauss and colleagues from Germany identified predictive factors for

sustained virological response with peginterferon plus ribavirin in patients

with chronic hepatitis C treated under ‘real-life’ conditions.

>

> The study cohort consisted of patients from a large, retrospective German

multicentre, observational study who had been treated with peginterferon alfa-2a

plus RBV or peginterferon alfa-2b plus ribavirin between the years 2000 and

2007.

>

> To ensure comparability regarding peginterferon therapies, patients were

analyzed in pairs matched by several baseline variables.

> Sustained virological response rates were 58% overall

> Journal of Viral Hepatitis

>

> The researchers determined the effect of nonmatched baseline variables and

treatment modality on sustained virological response.

>

> Among 2378 patients, sustained virological response rates were 58% overall,

47% in HCV genotype 1/4-infected patients and 77% in genotype 2/3-infected

patients.

>

> In multivariate logistic regression analysis, positive predictors of sustained

virological response were HCV genotype 2 infection, HCV genotype 3 infection,

low baseline viral load and treatment with peginterferon alfa-2a.

>

> The research team found that the negative predictors of sustained virological

response were higher age, elevated baseline gamma-glutamyl transpeptidase and

low baseline platelet count.

>

> Dr Mauss' team commented, " Among patients treated with peginterferon plus

ribavirin in routine clinical practice, genotype, baseline viral load, age,

gamma-glutamyl transpeptidase level and platelet levels all predict the

likelihood of treatment success. "

>

> " In patients matched by baseline characteristics, treatment with peginterferon

alfa-2a may be a positive predictor of sustained virological response when

compared to peginterferon alfa-2b. "

>

>

> http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01372.x/abstract

>  

>

http://Hepatitis Cnewdrugs.blogspot.com/2011/04/predicting-sustained-virological.\

html

>  

>  

>